Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?
How US Commercial Payers Will Manage Rapidly Increasing Drug Costs
Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.
You may also be interested in...
Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.
The European Medicines Agency says that the current shortage of antibiotics containing amoxicillin is not a “major event” and that efforts by EU and national regulators are helping to mitigate the situation.